A Phase 3 interventional study of Insulin Glargine and LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 101 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 9th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 884 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 32nd largest by enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2010, is one of 85 in phase 3, and was the 52nd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of LY2189265 in comparison to Insulin Glargine, both in combination with Insulin Lispro (plus or minus Metformin), in participants with Type 2 Diabetes treated with 1 or 2 injections of insulin.
The term rescue therapy in this trial was defined as therapy for participants who met criteria for persistent severe hyperglycemia and therapy for participants who required new intervention for any other reason. The latter included participants who discontinued study drug due to adverse events, participant decision, or any other reason. For efficacy analyses, participants who received rescue medication were included in the analysis population, but only measurements obtained prior to taking rescue therapy were included in the efficacy analysis. For safety analyses, with the exception of hypoglycemia, all measurements including those obtained after taking rescue therapy were included in the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks
Drug: LY2189265 · Drug: Insulin Lispro
LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks
Drug: LY2189265 · Drug: Insulin Lispro
Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks
Drug: Insulin Glargine · Drug: Insulin Lispro
Also known as: Dulaglutide
Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.
Time frame: Baseline, 26 weeks
Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c)
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.
Time frame: Baseline, 52 weeks
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at Weeks 26 and 52
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.
Time frame: 26 weeks and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than 7% Without Nocturnal or Severe Hypoglycemia
The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Fasting Serum Glucose
Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Total Daily Insulin Dose Overall and by Components (Insulin Lispro and Insulin Glargine)
Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.
Time frame: Baseline and 26 weeks and 52 weeks
Change From Baseline to 26 and 52 Weeks in Body Weight
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Body Weight at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Time frame: Baseline and 52 weeks and 4 weeks after last dose
Change From Baseline to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose in Body Mass Index (BMI)
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the EQ-5D
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Activities of Daily Living (IW-ADL)
The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Impact of Weight on Self-Perception (IW-SP)
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in the Low Blood Sugar Survey (LBSS)
The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Pancreatic Enzymes
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.
Time frame: Baseline, 26 weeks, and 52 weeks
Pancreatic Enzymes at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).
Time frame: Baseline and 52 weeks and 4 weeks after last dose
Change From Baseline to 26 and 52 Weeks in Serum Calcitonin
Time frame: Baseline, 26 weeks, and 52 weeks
Serum Calcitonin at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Time frame: Baseline and 52 weeks and 4 weeks after last dose
Change From Baseline to 26 and 52 Weeks in Blood Pressure
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Blood Pressure at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.
Time frame: Baseline and 52 weeks and 4 weeks after last dose
Change From Baseline to 26 and 52 Weeks in Pulse Rate
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate
Time frame: Baseline, 26 weeks, and 52 weeks
Pulse Rate at Baseline, 52 Weeks, and 4 Weeks After Last Dose
Seated pulse rate was measured.
Time frame: Baseline and 52 weeks and 4 weeks after last dose
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Change From Baseline to 26 and 52 Weeks in Electrocardiogram Parameters, Heart Rate
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.
Time frame: Baseline, 26 weeks, and 52 weeks
Number of Events of Adjudicated Pancreatitis up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Self-reported Hypoglycemic Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and 52 weeks
Rate of Self-reported Hypoglycemic Events up to 52 Weeks
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Adjudicated Cardiovascular Events up to 52 Weeks
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline through 4 weeks after last dose
Number of Participants With Treatment Emergent Adverse Events up to 26 Weeks, 52 Weeks, and 4 Weeks After Last Dose
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks, 52 weeks, and 4 weeks after last dose
| Milestone | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Started | 295 | 293 | 296 |
| Received at least one dose of study drug | 295 | 293 | 296 |
| Completed | 237 | 238 | 244 |
| Not completed | 58 | 55 | 52 |
| Withdrew: Withdrawal by subject | 19 | 25 | 21 |
| Withdrew: Adverse event | 21 | 13 | 8 |
| Withdrew: Physician decision | 6 | 8 | 9 |
| Withdrew: Lost to follow-up | 8 | 5 | 9 |
| Withdrew: Entry criteria not met | 3 | 1 | 1 |
| Withdrew: Death | 0 | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 2 | 0 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.64 ± 0.07 | -1.59 ± 0.07 | -1.41 ± 0.07 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, baseline metformin, and baseline HbA1c.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Change From Baseline to 52-week Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.48 ± 0.08 | -1.42 ± 0.08 | -1.23 ± 0.08 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| HbA1c less than 7.0%, 26 weeks | 67.6 | 69.0 | 56.8 |
| HbA1c less than 7.0%, 52 weeks | 58.5 | 56.3 | 49.3 |
| HbA1c less than or equal to 6.5%, 26 weeks | 48.0 | 43.0 | 37.5 |
| HbA1c less than or equal to 6.5%, 52 weeks | 36.7 | 34.7 | 30.4 |
The percentage of participants achieving HbA1c less than 7.0% without nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking) or severe (episodes requiring the assistance of another person to actively administer resuscitative actions) hypoglycemia was analyzed with a repeated logistic regression model (generalized estimating equation model) with baseline HbA1c, baseline metformin, country, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks | 53.8 | 54.5 | 28.2 |
| 52 weeks | 44.0 | 44.0 | 26.8 |
The self-monitored plasma glucose (SMPG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. The mean of the 8 time points (Daily Mean) was also calculated. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimoles per liter (mmol/L)] | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Pre-morning meal, 26 weeks (n=228, 231, 232) | -0.36 ± 0.14 | -0.06 ± 0.14 | -2.01 ± 0.14 |
| Post-morning meal, 26 weeks (n=220, 227, 229) | -3.70 ± 0.19 | -3.29 ± 0.19 | -4.03 ± 0.18 |
| Pre-midday meal, 26 weeks (n=227, 231, 233) | -2.80 ± 0.16 | -2.38 ± 0.16 | -2.65 ± 0.16 |
| Post-midday meal, 26 weeks (n=219, 227, 228) | -4.51 ± 0.17 | -4.53 ± 0.17 | -3.70 ± 0.17 |
| Pre-evening meal, 26 weeks (n=226, 231, 232) | -3.24 ± 0.16 | -3.06 ± 0.16 | -2.74 ± 0.16 |
| Post-evening meal, 26 weeks (n=220, 228, 227) | -4.61 ± 0.17 | -4.54 ± 0.17 | -3.90 ± 0.17 |
| Bedtime, 26 weeks (n=220, 221, 226) | -4.00 ± 0.17 | -3.89 ± 0.17 | -3.40 ± 0.17 |
| After bedtime, 26 weeks (n=208, 216, 208) | -1.48 ± 0.15 | -1.50 ± 0.15 | -1.96 ± 0.15 |
| Daily Mean, 26 weeks (n=202, 206, 199) | -3.17 ± 0.12 | -2.97 ± 0.12 | -3.10 ± 0.12 |
| Pre-morning meal, 52 weeks (n=207, 213, 218) | 0.03 ± 0.16 | 0.05 ± 0.15 | -2.02 ± 0.15 |
| Post-morning meal, 52 weeks (n=200, 211, 211) | -3.38 ± 0.19 | -3.23 ± 0.19 | -3.76 ± 0.19 |
| Pre-midday meal, 52 weeks (n=207, 213, 218) | -2.53 ± 0.14 | -2.52 ± 0.14 | -2.63 ± 0.14 |
| Post-midday meal, 52 weeks (n=202, 210, 212) | -4.33 ± 0.18 | -4.29 ± 0.18 | -3.83 ± 0.18 |
| Pre-evening meal, 52 weeks (n=207, 214, 217) | 3.00 ± 0.16 | -3.07 ± 0.16 | -2.67 ± 0.16 |
| Post-evening meal, 52 weeks (n=200, 210, 212) | -4.22 ± 0.17 | -4.54 ± 0.17 | -3.71 ± 0.16 |
| Bedtime, 52 weeks (n=195, 205, 213) | -3.62 ± 0.17 | -3.96 ± 0.17 | -3.27 ± 0.17 |
| After bedtime, 52 weeks (n=192, 192 197) | -1.17 ± 0.15 | -1.36 ± 0.15 | -1.80 ± 0.15 |
| Daily Mean, 52 weeks (n=182, 185, 189) | -2.84 ± 0.12 | -2.95 ± 0.12 | -2.97 ± 0.12 |
Fasting serum glucose was measured by the central laboratory. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline fasting blood glucose as a covariate.
| millimoles per liter (mmol/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=253, 256, 255) | -0.27 ± 0.20 | 0.22 ± 0.20 | -1.58 ± 0.20 |
| 52 weeks (n=237, 238, 246) | 0.08 ± 0.22 | 0.41 ± 0.22 | -1.01 ± 0.22 |
Total daily insulin (TDI) dose was reported at baseline, 26 weeks, and 52 weeks. Daily Insulin Lispro and Insulin Glargine doses were reported at 26 and 52 weeks.
| units | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| TDI, Baseline | 55.20 ± 32.17 | 59.11 ± 38.12 | 53.93 ± 30.67 |
| TDI, 26 weeks (n=244, 251, 254) | 93.24 ± 78.02 | 96.69 ± 62.13 | 132.00 ± 79.01 |
| TDI, 52 weeks (n=224, 227, 238) | 88.15 ± 62.95 | 95.00 ± 67.62 | 133.19 ± 80.75 |
| Insulin Lispro, 26 weeks (n=244, 251, 254) | 93.24 ± 78.02 | 96.69 ± 62.13 | 67.79 ± 44.59 |
| Insulin Lispro, 52 weeks (n=224, 227, 238) | 88.15 ± 62.95 | 95.00 ± 67.62 | 69.12 ± 49.07 |
| Insulin Glargine, 26 weeks (n=244, 251, 254) | NA ± NA | NA ± NA | 64.48 ± 40.23 |
| Insulin Glargine, 52 weeks (n=224, 227, 238) | NA ± NA | NA ± NA | 64.07 ± 38.60 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline body weight as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks | -0.87 ± 0.27 | 0.18 ± 0.27 | 2.33 ± 0.27 |
| 52 weeks | -0.35 ± 0.34 | 0.86 ± 0.33 | 2.89 ± 0.33 |
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Baseline | 91.00 ± 18.24 | 91.69 ± 18.03 | 90.75 ± 18.87 |
| 52 weeks (n=290, 290, 295) | 91.58 ± 19.06 | 93.21 ± 19.23 | 94.14 ± 19.72 |
| 4 weeks after last dose (n=259, 260, 253) | 91.69 ± 18.60 | 93.14 ± 19.20 | 94.27 ± 20.13 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline BMI as a covariate.
| kilograms per meter squared (kg/m^2) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=248, 251, 250) | -0.20 ± 0.09 | 0.21 ± 0.09 | 1.01 ± 0.09 |
| 52 weeks (n=225, 224, 232) | 0.09 ± 0.11 | 0.57 ± 0.11 | 1.33 ± 0.11 |
| 4 weeks after last dose | NA ± NA | NA ± NA | NA ± NA |
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusted by treatment, country, metformin use, and baseline.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| EQ-5D UK, 26 weeks (n=272, 271, 274) | -0.03 ± 0.01 | -0.03 ± 0.01 | -0.03 ± 0.01 |
| EQ-5D UK, 52 weeks (n=274, 274, 281) | -0.04 ± 0.01 | -0.04 ± 0.01 | -0.03 ± 0.01 |
| VAS, 26 weeks (n=278, 275, 275) | -1.69 ± 1.00 | -2.30 ± 1.00 | -0.60 ± 1.00 |
| VAS, 52 weeks (n=279, 278, 282) | -0.46 ± 1.01 | -2.54 ± 1.02 | -0.18 ± 1.01 |
The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire \[APPADL\]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=274, 270, 270) | -0.50 ± 0.30 | -0.60 ± 0.31 | -0.93 ± 0.31 |
| 52 weeks (n=277, 275, 279) | -0.50 ± 0.33 | -1.05 ± 0.33 | -1.28 ± 0.33 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment, and metformin use as fixed effects and baseline score as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=277, 274, 274) | 0.60 ± 0.17 | 0.34 ± 0.17 | 0.18 ± 0.17 |
| 52 weeks (n=278, 277, 281) | 0.86 ± 0.16 | 0.22 ± 0.16 | 0.06 ± 0.16 |
The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country, treatment and metformin use as fixed effects and baseline score as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=251, 256, 250) | 3.75 ± 1.31 | 2.91 ± 1.29 | 2.83 ± 1.30 |
| 52 weeks (n=234, 238, 244) | 2.51 ± 1.25 | 0.92 ± 1.23 | 2.38 ± 1.23 |
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured.
| units per liter (U/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Amylase (total), 26 weeks (n=284, 282, 287) | 5.00 (-2.00 to 15.00) | 4.00 (-1.00 to 10.00) | 1.00 (-4.00 to 8.00) |
| Amylase (total), 52 weeks (n=284, 283, 287) | 2.00 (-3.00 to 12.00) | 2.00 (-4.00 to 9.00) | 0.00 (-7.00 to 6.00) |
| Amylase (PD), 26 weeks (n=284, 282, 287) | 4.00 (0.00 to 10.00) | 2.50 (0.00 to 7.00) | 1.00 (-2.00 to 4.00) |
| Amylase (PD), 52 weeks (n=284, 283, 287) | 3.00 (-2.00 to 9.00) | 2.00 (-2.00 to 5.00) | 0.00 (-3.00 to 3.00) |
| Lipase, 26 weeks (n=284, 282, 287) | 7.00 (0.00 to 17.00) | 4.00 (-3.00 to 12.00) | -2.00 (-8.00 to 3.00) |
| Lipase, 52 weeks (n=284, 283, 287) | 6.00 (-1.00 to 16.50) | 3.00 (-3.00 to 11.00) | -2.00 (-9.00 to 4.00) |
Amylase (total and pancreas-derived \[PD\]) and lipase concentrations were measured at baseline and at 4 weeks after last dose (ALD).
| units per liter (U/L) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Amylase (total), Baseline | 61.21 ± 27.89 | 58.59 ± 23.19 | 61.18 ± 26.69 |
| Amylase (total), 52 weeks (n=284, 283, 287) | 66.08 ± 30.29 | 60.97 ± 25.78 | 61.93 ± 27.12 |
| Amylase (total), 4 weeks ALD (n=251, 259, 251) | 61.69 ± 28.06 | 59.21 ± 30.32 | 62.13 ± 26.11 |
| Amylase (PD), Baseline | 26.56 ± 14.51 | 25.10 ± 13.48 | 26.43 ± 15.94 |
| Amylase (PD), 52 weeks (n=284, 283, 287) | 31.38 ± 18.15 | 27.86 ± 17.14 | 26.91 ± 17.64 |
| Amylase (PD), 4 weeks ALD (n=251, 260, 251) | 27.50 ± 15.49 | 25.77 ± 13.78 | 26.84 ± 15.44 |
| Lipase, Baseline | 41.42 ± 34.19 | 41.08 ± 32.80 | 43.20 ± 37.35 |
| Lipase, 52 weeks (n=284, 283, 287) | 50.57 ± 35.65 | 45.34 ± 31.23 | 39.39 ± 27.51 |
| Lipase, 4 weeks ALD (n=252, 260, 251) | 44.19 ± 36.92 | 41.86 ± 25.22 | 43.02 ± 35.75 |
| picogram per milliliter (pcg/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=283, 282, 285) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| 52 weeks (n=283, 283, 285) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| picomole per liter | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Baseline | 0.75 ± 0.78 | 0.73 ± 0.77 | 0.78 ± 0.88 |
| 52 weeks (n=284, 283, 285) | 0.79 ± 0.89 | 0.78 ± 0.90 | 0.80 ± 0.89 |
| 4 weeks after last dose (n=245, 254, 246) | 0.76 ± 0.87 | 0.73 ± 0.72 | 0.87 ± 0.95 |
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline blood pressure as a covariate.
| milliliters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| SBP, 26 weeks (n=255, 261, 258) | -0.97 ± 0.88 | -0.65 ± 0.87 | 2.23 ± 0.88 |
| SBP, 52 weeks (n=239, 240, 246) | -0.26 ± 0.94 | 1.04 ± 0.93 | 1.98 ± 0.92 |
| DBP, 26 weeks (n=255, 261, 258) | 0.02 ± 0.56 | -0.08 ± 0.56 | -0.23 ± 0.56 |
| DBP, 52 weeks (n=239, 240, 246) | -0.01 ± 0.57 | 0.15 ± 0.57 | -0.34 ± 0.56 |
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured.
| milliliters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| SBP, Baseline | 133.26 ± 16.56 | 134.03 ± 15.87 | 133.26 ± 16.97 |
| SBP, 52 weeks (n=290, 290, 295) | 132.67 ± 15.40 | 134.31 ± 16.41 | 134.90 ± 16.25 |
| SBP, 4 weeks after last dose (n=260, 260, 255) | 133.77 ± 16.80 | 134.72 ± 16.50 | 132.75 ± 16.01 |
| DBP, Baseline | 77.33 ± 9.73 | 77.57 ± 9.00 | 77.18 ± 10.41 |
| DBP, 52 weeks (n=290, 290, 295) | 77.33 ± 9.63 | 77.59 ± 9.74 | 77.07 ± 9.92 |
| DBP, 4 weeks after last dose (n=260, 260, 255) | 76.58 ± 10.06 | 77.04 ± 9.60 | 76.94 ± 9.10 |
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline as a covariate
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=255, 261, 258) | 2.84 ± 0.57 | 2.79 ± 0.56 | 0.90 ± 0.56 |
| 52 weeks (n=239, 240, 246) | 2.38 ± 0.57 | 2.27 ± 0.57 | 0.93 ± 0.57 |
Seated pulse rate was measured.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Baseline | 75.26 ± 11.03 | 75.08 ± 11.10 | 74.54 ± 10.50 |
| 52 weeks (n=290, 290, 295) | 78.30 ± 11.01 | 77.83 ± 10.90 | 76.02 ± 11.43 |
| 4 weeks after last dose (n=260, 260, 255) | 74.52 ± 11.09 | 74.99 ± 11.98 | 75.27 ± 11.17 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.
| milliseconds (msec) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| QTcF interval, 26 weeks (n=241, 242, 236) | 0.29 ± 1.13 | 0.30 ± 1.12 | 1.59 ± 1.13 |
| QTcF interval, 52 weeks (n= 222, 221, 221) | 1.89 ± 1.13 | 1.48 ± 1.13 | 1.80 ± 1.14 |
| PR interval, 26 weeks (n=238, 243, 236) | 0.82 ± 0.95 | -1.75 ± 0.94 | -1.13 ± 0.95 |
| PR interval, 52 weeks (n=220, 222, 221) | 0.85 ± 1.00 | 0.05 ± 0.99 | -0.43 ± 1.00 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, metformin use, and treatment-by-visit interaction as fixed effects and baseline value as a covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks (n=244, 246, 243) | 3.95 ± 0.65 | 4.18 ± 0.65 | 1.37 ± 0.65 |
| 52 weeks (n=230, 226, 230) | 3.02 ± 0.67 | 3.83 ± 0.67 | 1.03 ± 0.67 |
The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks | NA | NA | NA |
| 52 weeks | 0 | 0 | 0 |
| 4 weeks after last dose | NA | NA | NA |
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The number of participants with self-reported hypoglycemic events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Severe HE, 26 weeks | 4 | 5 | 9 |
| Severe HE, 52 weeks | 8 | 7 | 14 |
| Severe HE, 4 weeks after last dose | NA | NA | NA |
| Documented Symptomatic HE, 26 weeks | 228 | 242 | 243 |
| Documented Symptomatic HE, 52 weeks | 235 | 250 | 247 |
| Documented Symptomatic HE, 4 weeks after last dose | NA | NA | NA |
| Asymptomatic HE, 26 weeks | 174 | 179 | 198 |
| Asymptomatic HE, 52 weeks | 191 | 196 | 207 |
| Asymptomatic HE, 4 weeks after last dose | NA | NA | NA |
| Total HE, 26 weeks | 250 | 258 | 264 |
| Total HE, 52 weeks | 252 | 263 | 266 |
| Total HE, 4 weeks after last dose | NA | NA | NA |
Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions and had a plasma glucose \[PG\] of ≤ 70 milligrams per deciliter \[mg/dL\]), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG of ≤ 70 mg/dL), or asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Severe HE | 0.03 ± 0.19 | 0.05 ± 0.50 | 0.08 ± 0.43 |
| Documented Symptomatic HE | 30.98 ± 39.64 | 35.03 ± 44.94 | 39.90 ± 50.92 |
| Asymptomatic HE | 9.55 ± 19.52 | 11.56 ± 24.69 | 14.20 ± 23.19 |
| Total HE | 41.52 ± 46.51 | 47.42 ± 54.39 | 55.93 ± 59.46 |
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| Any cardiovascular event | 5 | 6 | 12 |
| Any fatal cardiovascular event | 0 | 0 | 2 |
| Any non-fatal cardiovascular event | 5 | 6 | 11 |
A participant was considered to have treatment emergent LY2189265 anti-drug antibodies (ADA) if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| participants | 1.5 mg or 0.75 mg LY2189265 |
|---|---|
| 26 weeks | NA |
| 52 weeks | NA |
| 4 weeks after last dose | 9 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks, 52 weeks, and 4 weeks after last dose. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| 26 weeks | 203 | 216 | 178 |
| 52 weeks | 217 | 230 | 206 |
| 4 weeks after last dose | 223 | 235 | 211 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg LY2189265 | — | 27/295 (9.2%) | 219/295 (74.2%) |
| 0.75 mg LY2189265 | — | 46/293 (15.7%) | 232/293 (79.2%) |
| Insulin Glargine | — | 53/296 (17.9%) | 203/296 (68.6%) |
| Event | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 6/295 | 7/293 | 12/296 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/295 | 8/293 | 1/296 |
| PneumoniaInfections and infestations | 1/295 | 4/293 | 1/296 |
| Coronary artery diseaseCardiac disorders | 1/295 | 0/293 | 3/296 |
| MenorrhagiaReproductive system and breast disorders | 0/135 | 0/145 | 1/131 |
| Premenopausal menorrhagiaReproductive system and breast disorders | 0/135 | 0/145 | 1/131 |
| CholelithiasisHepatobiliary disorders | 0/295 | 2/293 | 0/296 |
| CellulitisInfections and infestations | 0/295 | 2/293 | 1/296 |
| GastroenteritisInfections and infestations | 0/295 | 2/293 | 0/296 |
| Urinary tract infectionInfections and infestations | 0/295 | 2/293 | 0/296 |
| Event | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine |
|---|---|---|---|
| NauseaGastrointestinal disorders | 76/295 | 52/293 | 9/296 |
| DiarrheaGastrointestinal disorders | 44/295 | 34/293 | 15/296 |
| VomitingGastrointestinal disorders | 35/295 | 31/293 | 5/296 |
| NasopharyngitisInfections and infestations | 22/295 | 1/293 | 33/296 |
| Common coldInfections and infestations | 19/295 | 28/293 | 26/296 |
| HeadacheNervous system disorders | 16/295 | 20/293 | 17/296 |
| Oedema peripheralGeneral disorders | 7/295 | 17/293 | 9/296 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/295 | 4/293 | 16/296 |
| Urinary tract infectionInfections and infestations | 12/295 | 14/293 | 11/296 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/295 | 13/293 | 8/296 |
Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.
| Age, Continuous(years) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 58.88 ± 9.55 | 59.31 ± 8.98 | 59.90 ± 9.08 | 59.36 ± 9.21 |
| Sex: Female, Male(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Female | 135 | 145 | 131 | 411 |
| Male | 160 | 148 | 165 | 473 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Hispanic or Latino | 102 | 101 | 100 | 303 |
| Not Hispanic or Latino | 193 | 192 | 196 | 581 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 16 | 13 | 17 | 46 |
| Asian | 9 | 12 | 14 | 35 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 32 | 27 | 26 | 85 |
| White | 231 | 235 | 231 | 697 |
| More than one race | 7 | 6 | 7 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| United States | 103 | 95 | 96 | 294 |
| Taiwan | 8 | 9 | 9 | 26 |
| Greece | 8 | 7 | 8 | 23 |
| Spain | 8 | 10 | 9 | 27 |
| Russian Federation | 6 | 8 | 9 | 23 |
| Hungary | 19 | 19 | 19 | 57 |
| Mexico | 19 | 19 | 17 | 55 |
| Canada | 9 | 8 | 9 | 26 |
| Puerto Rico | 13 | 20 | 18 | 51 |
| Argentina | 26 | 27 | 28 | 81 |
| Poland | 13 | 13 | 14 | 40 |
| Brazil | 33 | 30 | 32 | 95 |
| Belgium | 5 | 5 | 4 | 14 |
| Denmark | 4 | 4 | 4 | 12 |
| Australia | 10 | 8 | 8 | 26 |
| Sweden | 11 | 11 | 12 | 34 |
| Body Weight(kilograms (kg)) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 91.00 ± 18.24 | 91.69 ± 18.03 | 90.75 ± 18.87 | 91.14 ± 18.37 |
| Body Mass Index (BMI)(kilograms per square meter (kg/m^2)) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 31.99 ± 5.11 | 33.08 ± 5.15 | 32.41 ± 5.33 | 32.49 ± 5.21 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 8.46 ± 1.08 | 8.40 ± 1.03 | 8.53 ± 1.03 | 8.46 ± 1.05 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 101 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2010, a primary completion of Feb 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 8 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide